Socioeconomic and clinical factors explaining the risk of unstructured antiretroviral therapy interruptions among Kenyan adult patients

References

• Boyer, S., Clerc, I., Bonono, C.-R., Marcellin, F., Bilé, P.-C., & Ventelou, B. (2011). Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. Social Science & Medicine, 72(8), 1383–1392. doi:10.1016/j.socscimed.2011.02.030
   PubMed Web of Science ®Google Scholar
• Claborn, K. R., Meier, E., Miller, M. B., & Leffingwell, T. R. (2014). A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychology, Health & Medicine, 20(3), 255–265. doi:10.1080/13548506.2014.945601
   PubMed Web of Science ®Google Scholar
• Clumeck, N., Pozniak, A., Raffi, F., & the EACS Executive Committee. (2008). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Medicine, 9(2), 65–71. doi:10.1111/j.1468-1293.2007.00533.x
   PubMed Web of Science ®Google Scholar
• Commission on Revenue Allocation. (2012). Kenya County Fact Sheets (p. 8). Nairobi, Kenya: Government of Kenya. Retrieved from http://kenya.usaid.gov/sites/default/files/profiles/Nyeri%20County%2023%20Jan%202012.pdf
   Google Scholar
• DART Trial Team. (2008). Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts< 200 cells/μl. AIDS, 22(2), 237–247. doi:10.1097/QAD.0b013e3282f2d760
   PubMed Web of Science ®Google Scholar
• Dawson, N. V., & Weiss, R. (2012). Dichotomizing continuous variables in statistical analysis: A practice to avoid. Medical Decision Making, 32(2), 225–226. doi:10.1177/0272989X12437605
   PubMed Web of Science ®Google Scholar
• Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group. (2008). British HIV association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine, 9(8), 563–608. doi:10.1111/j.1468-1293.2008.00636.x
   PubMed Web of Science ®Google Scholar
• Hirschel, B. (2001). Planned interruptions of anti-HIV treatment. The Lancet. Infectious Diseases, 1(1), 53–59. doi:10.1016/S1473-3099(01)00022-6
   PubMedGoogle Scholar
• Holkmann Olsen, C., Mocroft, A., Kirk, O., Vella, S., Blaxhult, A., Clumeck, N., … for the EuroSIDA study group. (2007). Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine, 8(2), 96–104. doi:10.1111/j.1468-1293.2007.00436.x
   PubMed Web of Science ®Google Scholar
• Horvath, T., Azman, H., Kennedy, G. E., & Rutherford, G. W. (2012). Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database of Systematic Reviews. Wiley. Retrieved from http://onlinelibrary.wiley.com.ludwig.lub.lu.se/doi/10.1002/14651858.CD009756/abstract
   Google Scholar
• Imaz, A., Olmo, M., Peñaranda, M., Gutiérrez, F., Romeu, J., Larrousse, M., … STOPAR study team. (2013). Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. Antiviral Therapy, 18(1), 125–130. doi:10.3851/IMP2249
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS. (2013). How Africa turned AIDS around (Special report). Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved from http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2013/20130521_Update_Africa.pdf
   Google Scholar
• Kranzer, K., & Ford, N. (2011). Unstructured treatment interruption of antiretroviral therapy in clinical practice: A systematic review. Tropical Medicine & International Health, 16(10), 1297–1313. doi:10.1111/j.1365-3156.2011.02828.x
   PubMed Web of Science ®Google Scholar
• Kranzer, K., Lewis, J. J., Ford, N., Zeinecker, J., Orrell, C., Lawn, S. D., … Wood, R. (2010). Treatment interruption in a primary care antiretroviral therapy programme in South Africa: Cohort analysis of trends and risk factors. Journal of Acquired Immune Deficiency Syndromes (1999), 55(3), e17–e23. doi:10.1097/QAI.0b013e3181f275fd
   PubMed Web of Science ®Google Scholar
• Krentz, H. B., & Gill, M. J. (2003). The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients [Letter]. AIDS, 17(4), 631–633.
   Google Scholar
• Lisziewicz, J., & Lori, F. (2002). Structured treatment interruptions in HIV/AIDS therapy. Microbes and Infection, 4(2), 207–214. doi:10.1016/S1286-4579(01)01529-5
   PubMed Web of Science ®Google Scholar
• Lwanga, S. K., & Lemeshow, S. (1991). Sample size determination in health studies: A practical manual. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Mann, M., Lurie, M. N., Kimaiyo, S., & Kantor, R. (2013). Effects of political conflict induced treatment interruptions on HIV drug resistance. AIDS Reviews, 15(1), 15–24.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Kenya, & National AIDS and STI Control Programme. (2014). Guidelines on use of antiretroviral drugs for treating and preventing HIV infection: A rapid advice, 2014. Nairobi: National AIDS and STI Control Programme (NASCOP). Retrieved from http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Rapid%20Advice%20Booklet%202014%2024%20June%2012%20noon_0.pdf
   Google Scholar
• Mûnene, E., & Ekman, B. (2014a). Association between patient engagement in HIV care and antiretroviral therapy medication adherence: Cross-sectional evidence from a regional HIV care center in Kenya. AIDS Care, 27(3), 378–386. doi:10.1080/09540121.2014.963020
   PubMed Web of Science ®Google Scholar
• Mûnene, E., & Ekman, B. (2014b). Does duration on antiretroviral therapy determine health-related quality of life in people living with HIV? A cross-sectional study in a regional referral hospital in Kenya. Global Health Action, 7. doi:10.3402/gha.v7.23554
   PubMed Web of Science ®Google Scholar
• National AIDS and STI Control Programme, Kenya. (2011). Guidelines for antiretroviral therapy in Kenya (4th ed.). Nairobi: National AIDS and STI Control Program (NASCOP). Retrieved from http://www.faces-kenya.org/wp-content/uploads/2012/12/Kenya-Treatment-Guidelines_4th-edition-2011.pdf
   Google Scholar
• National AIDS and STI Control Programme, Kenya. (2014a). Kenya HIV estimates. Nairobi: National AIDS and STI Control Program (NASCOP). Retrieved from http://www.nacc.or.ke/attachments/article/428/HIV%20estimates%20report%20Kenya%202014_print.pdf
   Google Scholar
• National AIDS and STI Control Programme, Kenya. (2014b). Kenya AIDS indicator survey 2012: Final report. Nairobi: Author. Retrieved from http://www.nacc.or.ke/attachments/article/403/KAIS_II_2014_Final_Report.pdf
   Google Scholar
• National AIDS Control Council. (2014). Kenya HIV county profiles. Nairobi: Author. Retrieved from http://www.nacc.or.ke/attachments/article/464/Kenya%20County%20Profiles%20Book_Nov_print.pdf
   Google Scholar
• Oyugi, J. H., Byakika-Tusiime, J., Ragland, K., Laeyendecker, O., Mugerwa, R., Kityo, C., … Bangsberg, D. R. (2007). Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS, 21(8), 965–971. doi:10.1097/QAD.0b013e32802e6bfa
   PubMed Web of Science ®Google Scholar
• Palladino, C., Briz, V., Bellón, J. M., Climent, F. J., de Ory, S. J., Mellado, M. J., … on the behalf of the CoRISpeS-Madrid Cohort Working Group. (2014). Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012. PLoS One, 9(5), e96307. doi:10.1371/journal.pone.0096307
   Google Scholar
• Pop-Eleches, C., Thirumurthy, H., Habyarimana, J. P., Zivin, J. G., Goldstein, M. P., de Walque, D., … Bangsberg, D. R. (2011). Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: A randomized controlled trial of text message reminders. AIDS (London, England), 25(6), 825–834. doi:10.1097/QAD.0b013e32834380c1
   PubMed Web of Science ®Google Scholar
• Prosperi, M. C., Fabbiani, M., Fanti, I., Zaccarelli, M., Colafigli, M., Mondi, A., … Di Giambenedetto, S. (2012). Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infectious Diseases, 12(1), 296. doi:10.1186/1471-2334-12-296
   PubMed Web of Science ®Google Scholar
• Sommet, A., Delpierre, C., Cuzin, L., Jaafar, A., Marchou, B., & Massip, P. (2003). Anti-retroviral treatment interruptions in HIV-infected adults: Causes, clinical, immunological and virological consequences. La Revue De Médecine Interne/Fondée … Par La Société Nationale Francaise De Médecine Interne, 24(6), 350–357.
   PubMed Web of Science ®Google Scholar
• Steingrover, R., Pogány, K., Fernandez Garcia, E., Jurriaans, S., Brinkman, K., Schuitemaker, H., … Prins, J. M. (2008). HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS, 22(13), 1583–1588. doi:10.1097/QAD.0b013e328305bd77
   PubMed Web of Science ®Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. (2008). Inferior clinical outcome of the CD4+ Cell count–guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up. Journal of Infectious Diseases, 197(8), 1145–1155. doi:10.1086/529523
   PubMed Web of Science ®Google Scholar
• Taffé, P., Rickenbach, M., Hirschel, B., Opravil, M., Furrer, H., Janin, P., … Swiss HIV Cohort Study. (2002). Impact of occasional short interruptions of HAART on the progression of HIV infection: Results from a cohort study. AIDS (London, England), 16(5), 747–755.
   PubMed Web of Science ®Google Scholar
• Touloumi, G., Pantazis, N., Antoniou, A., Stirnadel, H. A., Walker, S. A., & Porter, K. (2006). Highly active antiretroviral therapy interruption: Predictors and virological and immunologic consequences. JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(5), 554–561. doi:10.1097/01.qai.0000230321.85911.db
   PubMed Web of Science ®Google Scholar
• Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. doi:10.2307/3765916
   PubMed Web of Science ®Google Scholar
• Yazdanpanah, Y., Wolf, L. L., Anglaret, X., Gabillard, D., Walensky, R. P., Moh, R., … the CEPAC-International Investigators. (2010). CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials. Antiviral Therapy, 15(3), 351–361. doi:10.3851/IMP1542
   PubMed Web of Science ®Google Scholar
• Yuan, Y., L'Italien, G., Mukherjee, J., & Iloeje, U. (2006). Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort*. HIV Medicine, 7(3), 156–162. doi:10.1111/j.1468-1293.2006.00355.x
   PubMed Web of Science ®Google Scholar